FDA Approved: ILEVRO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for ILEVRO (nepafenac) by Novartis Pharmaceuticals Corporation. This indicates a labeling change for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• ILEVRO (nepafenac)

Snippet

SUPPL AP for ILEVRO (NEPAFENAC)